Antinuclear antibody (ANA) HEp-2 testing in patients with multiple myeloma
DOI:
https://doi.org/10.1590//s2175-97902025e24706Keywords:
Antinuclear antibody, Oncohematology, Prognosis, Multiple myelomaAbstract
Antinuclear antibodies (ANAs) have recently sparked interest given their presence in cancer, including multiple myeloma (MM), a hematologic neoplasm characterized by abnormal plasma cell proliferation that accounts for approximately 1.6% of all cases of cancer. In our study, we performed ANA HEp-2 assays on samples from 44 patients with MM, 17 healthy controls, and a group of post-chemotherapy patients. Results revealed a significantly higher prevalence of ANAs in patients with MM than in controls (p = 0.0059). Most patients with MM exhibited relatively high ANA titers (≥1:80), and the most prevalent fluorescence pattern was the fine nuclear dot pattern. Notably, ANA titers decreased following chemotherapy, which correlated with the decrease in B2-microglobulin as well. Altogether, our results indicate potential links between a high prevalence of ANAs in patients with MM and frequent ANA positivity in metaphasic plaques.
Downloads
References
Akmatov MK, Röber N, Ahrens W, Janys DF, Fricke J, Greiser H, et al. Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders—findings of a multicenter population-based study. Arthritis Res Ther. 2017;19(1):127.
Al-Shukaili AK, Al-Jabri AA, Al-Moundhri MS. Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. Saudi Med J. 2006;27(12):1873-7.
Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg. 2000;69(1):254-8.
Brito FA, Santos SME, Ferreira GA, Pedrosa W, Gradisse J, Costa LC, et al. Detection of anti-nuclear antibodies by indirect immunofluorescence on HEp-2 cells: setting the appropriate screening dilution for the diagnosis of autoimmune rheumatic diseases. Rev Bras Reumatol. 2013;54(1):13-20.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next generation immunotherapy: inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-7.
Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14-26.
Dinse GE, Parks CG, Weinberg CR, Meier HCS, Co CA, Chan EKL, et al. Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). PLoS One. 2017;12(10):1-15.
Giannicola R, D’Arrigo G, Botta C, Agostino R, Medico PD, Falzea AC, et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. Mol Clin Oncol. 2019;11(1):81-90.
Guyomard S, Salles G, Coudurier M, Rousset H, Coiffier B, Bienvenu J, et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Br J Haematol. 2003;123(1):90-
Heegaard NHH, Norager MW, Tanassi JT, Houen G, Nedergaard L, Hogdall C, et al. Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. PLoS One. 2012;7(2):1-7.
International Consensus on Antinuclear Antibody Standards (ICAP). Available from: https://www.anapatterns.org/index.php. [cited 2019 Jan 27]
Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676-81.
Madrid FF, Maroun MC, Olivero OA, Long M, Stark A, Grossman LI, et al. Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer. 2015;15(1):407.
Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373-83.
Downloads
Published
Data Availability Statement
Declaração ausente.
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
